Boehringer Ingelheim of Germany has announced plans to collaborate with the privately-held US firm, Vitae Pharmaceuticals Inc, to investigate beta-secretase inhibitors for the treatment of Alzheimer’s disease.
Allergy Therapeutics Plc is proposing to raise up to £22.4 million in a private share placement which would give a group of South American investors up to 49.65% of the group’s enlarged share capital.
A US company with novel technology for making peptide drugs has received $40 million in a Series D funding from a syndicate that includes the venture capital arms of four major pharmaceutical companies.
A British medical discovery company with 25 employees, a history of losses and no products under clinical development is about to raise £50 million through a share sale on Britain’s junior stock market
The Wellcome Trust has awarded €5.15 million to a vaccine institute run by Novartis AG to investigate a new bivalent vaccine for Typhoid fever.
The US Food and Drug Administration has asked Genmab A/S for an updated analysis of safety data for the monoclonal antibody, zalutumumab, which is being investigated for head and neck cancer.
In a second collaboration between two Big Pharma companies this year, AstraZeneca Plc and Merck & Co have announced plans to investigate the possible use of their respective, early-stage cancer treatments together, as a co-administered treatment.
GlaxoSmithKline has announced a collaboration worth up to $1 billion with Concert Pharmaceuticals of Lexington, Mass, involving the use of deuterium chemistry to create novel small molecule drugs.
The European Medicines Agency has given positive opinions to three new drugs, two of which are intended for patients suffering from cancer. The agency also recommended new uses for three already approved drugs.
GPC Biotech AG said that the new Germany-based biotechnology company that will be created following its merger with Agennix Inc of Texas should have enough cash to fund operations into the second quarter of 2010.